Very Impressive...
Having been involved in several bio-tech and device companies, just browsing through the information one of the items that sticks out in my mind.
The fact that they will be targeting the U.S. and China at the same time.
I cant tell you how many times a U.S. based company gets log jammed in the FDA approval process and to keep the interest of investors they talk about targeting China and Europe (someday) because its easier and quicker through a more efficient process to get products approved and to market. Of course China is always mentioned because of the large demographics.
GLGT will be in China day one. Targeting China and U.S. at the same time. I believe this is huge.
Cardiovascular is huge and with the growing health care costs related to strokes and heart attacks early detection and action is the key to survival and recovery.
They already have patents targeting various key areas as well.
Just think, we sit here at .0023 today. LOL You have to laugh at this. How many r/m's occur with this type of potential with product already developed.
If they have any revenues at all it should exponentially increase value. Then add to it the patents and target markets and the speculation power of bio-tech its hard to figure how they could keep GLGT under a penny let alone value you it in multi-pennies.
The biggest way to increase value for GLGT today is massive market awareness and folks that is beginning to happen as we speak...
Now add the potential for solar. Like I said in an earlier post, with another subsidiary added in the solar arena, all I can say is, GAME OVER, multi-penny and up, from a pure valuation perspective....
All just my humble opinion but all you have to do is do your own DD and look around.
Have a great Easter weekend all!!!
